基于肝窦毛细血管化探讨抗纤软肝方抗肝纤维化的作用机制

许杰; 刘艳; 楼汪洲洋; 徐俊; 戚露; 程良斌

doi:10.3969/j.issn.1001-5256.2020.02.017

基于肝窦毛细血管化探讨抗纤软肝方抗肝纤维化的作用机制

DOI: 10.3969/j.issn.1001-5256.2020.02.017

1. 湖北中医药大学中医临床学院
2. 宜昌市中医医院脾胃科
3. 湖北中医药大学信息工程学院
4. 湖北中医药大学感染病学教研室
5. 湖北省中医院肝病科，湖北省中医院肝病研究所

基金项目:

国家中医药管理局国家中医临床研究基地业务建设科研专项(JDZX2015179)；王伯祥全国名老中医药专家工作室(国中医药办人教函〔2018〕119号)；

详细信息

中图分类号: R575.2
计量
- 文章访问数: 1289
- HTML全文浏览量: 56
- PDF下载量: 225
- 被引次数: 0
出版历程
- 收稿日期: 2019-09-15
- 出版日期: 2020-02-20

The anti-liver fibrosis effect of Kangxian Ruangan prescription: A cell study based on hepatic sinusoidal capillarization

Clinical College of Traditional Chinese Medicine,Hubei University of Chinese Medicine

Research funding:

摘要

摘要:
目的基于肝窦毛细血管化探讨抗纤软肝方抗肝纤维化的作用及机制。方法将16只Wistar雄性大鼠分为抗纤软肝方组和对照组,每组各8只。抗纤软肝方组生药40 g/kg大鼠体质量灌胃,对照组用生理盐水给大鼠灌胃。将抗纤软肝方制备成含药血清与对照血清分别处理原代肝窦内皮细胞模型。采用Western-Blot检测血管内皮标志物分化抗原簇31（CD31）和血管性血友病因子（vWF）的蛋白表达水平;采用免疫细胞化学的方法检测细胞中CD31、vWF的细胞因子表达水平。扫描电镜检测肝窦内皮细胞窗孔的变化。计量资料两组间比较采用t检验。结果抗纤软肝方对肝窦内皮细胞形态学无明显影响。对照组肝窦内皮细胞窗孔狭小,结构将近闭塞,数量较少;抗纤软肝方组肝窦内皮细胞窗孔结构清晰,窗孔增多增大,明显可见。免疫细胞化学测定结果显示:与对照组比较,抗纤软肝方组CD31和vWF表达水平显著降低（CD31:0. 069±0. 015 vs 0. 115±0. 011,t=4. 257,P <0. 05;vWF:0. 092±0. 009 vs 0. 132±0. 014,t=4. 274,P <0. 05）。Wes...
- 肝硬化 /
- 抗纤软肝方 /
- 抗原,CD31 /
- von Willebrand因子 /
- 大鼠,Wistar
Abstract:
Objective To investigate the anti-liver fibrosis effect and mechanism of action of Kangxian Ruangan prescription based on hepatic sinusoidal capillarization. Methods A total of 16 male Wistar rats were divided into Kangxian Ruangan prescription group and control group,with 8 rats in each group. The rats in the Kangxian Ruangan prescription group were given crude drug 40 g/kg body weight by gavage,and those in the control group were given normal saline by gavage. Serum containing Kangxian Ruangan prescription was prepared,and then primary liver sinusoidal endothelial cells were treated with the serum containing Kangxian Ruangan prescription or the control serum. Western blot was used to measure the protein expression of the vascular endothelial markers cluster of differentiation 31( CD31) and von Willebrand factor( vWF),and immunocytochemistry was used to measure the expression of CD31 and vWF in cells. Scanning electron microscopy was used to observe the change in the fenestrae of liver sinusoidal endothelial cells. The t-test was used for comparison of continuous data between two groups. Results Kangxian Ruangan prescription had no marked influence on the morphology of liver sinusoidal endothelial cells. The liver sinusoidal endothelial cells in the control group had a small number of narrow fenestrae with an occluded structure,while those in the Kangxian Ruangan prescription group had an increased number of large fenestrae with a clear structure. The results of immunocytochemistry showed that compared with the control group,the Kangxian Ruangan prescription group had significant reductions in the expression of CD31( 0. 069 ± 0. 015 vs 0. 115 ± 0. 011,t = 4. 257,P < 0. 05) and vWF( 0. 092 ± 0. 009 vs 0. 132 ± 0. 014,t = 4. 274,P < 0. 05). The results of Western blot showed that compared with the control group,the Kangxian Ruangan prescription group had significant reductions in the protein expression of CD31( 0. 334 ± 0. 029 vs 0. 448 ± 0. 013,t = 6. 245,P < 0. 01) and vWF( 0. 560 ± 0. 047 vs0. 709 ± 0. 045,t = 3. 966,P < 0. 05). Conclusion Kangxian Ruangan prescription can significantly resist hepatic sinusoid capillarization and thus prevent the progression of liver fibrosis.
- liver cirrhosis /
- Kangxian ruangan decoction /
- antigens,CD31 /
- von Willebrand factor /
- rats,Wistar

HTML全文

参考文献(27)

[1] ZHOU XG,LIU HG. Hedgehog signaling pathway in liver diseases[J/CD]. Chin J Liver Dis(Electronic Version),2017,9(3):30-35.(in Chinese)周新刚，刘红刚．Hedgehog信号通路在肝脏疾病中的研究进展[J/CD]．中国肝脏病杂志(电子版)，2017,9(3):30-35.

[2] IREDALE JP. Models of liver fibrosis:Exploring the dynamic nature of inflammation and repair in a solid organ[J]. J Clin Invest,2007,117(3):539-548.

[3] SCHUPPAN D,KIM YO. Evolving therapies for liver fibrosis[J]. J Clin Invest,2013,123(5):1887-1901.

[4] GU L,TAO X,XU Y,et al. Dioscin alleviates BDL-and DMN-induced hepatic fibrosis via Sirt1/Nrf2-mediated inhibition of p38 MAPK pathway[J]. Toxicol Appl Pharmacol,2016,292:19-29.

[5] SUN NN,SUN FX,LI XL,et al. Significance of the treatment of basic liver diseases in primary liver cancer[J/CD]. Chin J Liver Dis(Electronic Version),2018,10(1):6-9.(in Chinese)孙宁宁，孙凤霞，李晓玲，等．原发性肝癌基础肝病治疗的意义[J/CD]．中国肝脏病杂志(电子版)，2018,10(1):6-9.

[6] LYU GS,CHEN L,WANG HY. Research progress and prospect of liver cancer in China[J]. Chin Bull Life Sci,2015,27(3):237-248.(in Chinese)吕桂帅，陈磊，王红阳．我国肝癌研究的现状与前景[J]．生命科学，2015,27(3):237-248.

[7] ZHANG H,TAO S,HAO Y,et al. Research highlights analysis of foreign liver fibrosis diagnosis[J]. J Capital Medical University,2016,37(1):83-88.(in Chinese)张弘，陶森，郝彧，等．国外肝纤维化诊断的研究热点分析[J]．首都医科大学学报，2016,37(1):83-88.

[8] XIE ZB,YU YQ,FENG DY,et al. Fuzheng Huayu recipe promotes the fenestration of capillarization in Iiver sinusoidal endothelial cells[J]. J Cent South Univ:Med Sci,2015,40(7):723-728.(in Chinese)谢知兵，余燕青，冯德云，等．扶正化瘀方增加毛细血管化肝窦内皮细胞窗孔结构[J]．中南大学学报:医学版，2015,40(7):723-728.

[9] JIA YT,ZENG MD. Research progress of hepatic sinusoidal capillarization[J]. Foreign Med Sci:Digive System Dis,2000,20(2):86-90.(in Chinese)贾一韬，曾明德．肝窦毛细血管化的研究进展[J]．国外医学:消化系疾病分册，2000,20(2):86-90.

[10] XU MX,XU RY,LIN N,et al. Research progress of hepatic sinusoidal capillarization[J]. Organ Transplantation,2016,7(5):403-406.(in Chinese)许明星，许瑞云，林楠，等．肝窦毛细血管化研究进展[J]．器官移植，2016,7(5):403-406.

[11] ZHANG CZ,WANG L. 31 cases of liver cirrhosis treated by anti-fibrosis and soft liver impulse[J]. Chin J Integr Tradit West Med Liver Dis,1999,9(2):19-20.(in Chinese)张赤志，王丽．抗纤软肝冲击治疗肝硬变31例[J]．中西医结合肝病杂志，1999,9(2):19-20.

[12] CHENG LB,CHENG M,LIU Y,et al. The effect of Kangxian Ruangan granule on the expression of nuclear factor-κB in fibrotic rat liver[J]. J Clin Hepatol,2010,26(4):410-412.(in Chinese)程良斌，程铭，刘艳，等．抗纤软肝颗粒对肝纤维化大鼠肝组织核因子-κB基因表达的影响[J]．临床肝胆病杂志，2010,26(4):410-412.

[13] CAI YP,CHENG LB,LI ZW,et al. Effects of Kangxian Ruangan granule on hepatic stellate cell cycle of rat[J]. Chin J Integr Tradit West Med Liver Dis,2013,23(4):234-236.(in Chinese)蔡艳萍，程良斌，李志伟，等．抗纤软肝颗粒对大鼠肝星状细胞周期的影响[J]．中西医结合肝病杂志，2013,23(4):234-236.

[14] HUANG LW,CHENG LB. Advances in anti-hepatic fibrosis of traditional Chinese medicine targeting hepatic stellate cells[J]. Chin J Integr Tradit West Med Liver Dis,2007,17(3):191-193.(in Chinese)黄丽雯，程良斌．中药以肝星状细胞为靶点的抗肝纤维化研究进展[J]．中西医结合肝病杂志，2007,17(3):191-193.

[15] CHENG LB,LI ZW. Effect of Kangxian Ruangan granule on HSC nucleolar non-histone protein B23 and C23 of rats[J]. Chin J Integr Tradit West Med Liver Dis,2010,20(5):291-293.(in Chinese)程良斌，李志伟．抗纤软肝颗粒对大鼠肝星状细胞核仁非组蛋白B23和C23的影响[J]．中西医结合肝病杂志，2010,20(5):291-293.

[16] YAN JS,ZHOU JH,CHENG LB. Effect of Kangxian Ruangan granules on hepatic fibrosis induced by carbon tetrachloride and ethanol[J]. Chin J Integr Tradit West Med Liver Dis,2017,27(1):40-41,49.(in Chinese)严俊松，周金辉，程良斌．抗纤软肝颗粒对四氯化碳加乙醇诱导肝纤维化大鼠的影响[J]．中西医结合肝病杂志，2017,27(1):40-41,49.

[17] JIANG MH,LIU L,MENG YP,et al. Clinical study of Kangxian Ruangan granule in the treatment of liver fibrosis[J]. Guid J Tradit Chin Med Pharm,2016,22(14):81-83.(in Chinese)蒋满红，刘璐，孟艳平，等．抗纤软肝颗粒治疗肝纤维化的临床研究[J]．中医药导报，2016,22(14):81-83.

[18] LI ZW,CHENG LB. Effects of Kangxian Ruangan granule on rat hepatic stellate cell proliferation[J]. Chin J Integr Tradit West Med Liver Dis,2010,20(2):95-97.(in Chinese)李志伟，程良斌．抗纤软肝颗粒对大鼠肝星状细胞增殖的影响[J]．中西医结合肝病杂志，2010,20(2):95-97.

[19] Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenterology,Chinese Medical Association; Chinese Society of Infectious Diseases,Chinese Medical Association. Consensus on the diagnosis and therapy of hepatic fibrosis(2019)[J]. J Clin Hepatol,2019,35(10):2163-2172.(in Chinese)中华医学会肝病学分会，中华医学会消化病学分会，中华医学会感染病学分会．肝纤维化诊断及治疗共识(2019年)[J]．临床肝胆病杂志，2019,35(10):2163-2172.

[20] LOK AS. Hepatitis:Long-term therapy of chronic hepatitis B reverses cirrhosis[J]. Nat Rev Gastroenterol Hepatol,2013,10(4):199-200.

[21] MARCELLIN P,GANE E,BUTI M,et al. Regression of cirrhosisduring treatment with tenofovir disoproxil fumarate for chronic hepatitis B:A 5-year open label follow up study[J]. Lancet,2013,381(9865):468-475.

[22] CHANG TT,LIAW YF,WU SS,et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B[J]. Hepatology,2010,52(3):886-893.

[23] JIN WZ,TAN XC,WEN J,et al. Advances in nano-delivery systems targeting hepatic stellate cells for hepatic fibrosis[J].China Med Herald,2019,16(9):34-37.(in Chinese)靳雯臻，谭晓川，文瑾，等．靶向肝星状细胞治疗肝纤维化的纳米递送系统研究进展[J]．中国医药导报，2019,16(9):34-37.

[24] JIA JD,YIN SS. Diagnosis and treatment of liver fibrosis[J].J Clin Intern Med,2002,19(4):244-247.(in Chinese)贾继东，尹珊珊．肝纤维化的诊断和治疗进展[J]．临床内科杂志，2002,19(4):244-247.

[25] DENG C,YE BP. Research progress in mechanism and treatment of hepatic fibrosis[J]. Pharm Bio Technol,2017,24(5):454-458.(in Chinese)邓灿，叶波平．肝纤维化发生机制及治疗研究进展[J]．药物生物技术，2017,24(5):454-458.

[26] YU ZY,LIN X,HAN Y,et al. Role of liver sinusoidal endothelial cells in liver regeneration and the development of liver fibrosis[J]. J Clin Hepatol,2019,35(9):2072-2074．于子越，蔺鑫，韩英，等．肝血窦内皮细胞在肝再生和肝纤维化发生中的作用[J]．临床肝胆病杂志，2019,35(9):2072-2074.

[27] LU X,LIU P,LIU CH,et al. Experimental study on the effect of Fuzheng Huayu Recipe on reversing hepatic sinusoidal capillarization in rats with dimethylnitrosamine-induced hepatic fibrosis[J]. J Tradit Chin Med,2003,44(2):136-139.(in Chinese)陆雄，刘平，刘成海，等．扶正化瘀方促进二甲基亚硝胺肝纤维化大鼠肝窦毛细血管化逆转作用的实验研究[J]．中医杂志，2003,44(2):136-139.

施引文献

资源附件(0)

访问统计